Robert Michael Dudley - Jul 8, 2021 Form 3 Insider Report for Transcode Therapeutics, Inc. (RNAZ)

Role
Chief Executive Officer, Director, 10%+ Owner
Signature
/s/ Thomas A. Fitzgerald, Attorney-in-Fact
Stock symbol
RNAZ
Transactions as of
Jul 8, 2021
Transactions value $
$0
Form type
3
Date filed
7/8/2021, 09:54 PM
Next filing
Feb 3, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding RNAZ Common Stock 843K Jul 8, 2021 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding RNAZ Stock Option (Right to Buy) Jul 8, 2021 Common Stock 819K $0.09 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Thirty-three percent (33%) of the Stock Options shall vest and become exercisable on the Vesting Commencement Date (January 1, 2020). Thereafter, the remaining sixty-seven percent (67%) of the Stock Options shall vest and become exercisable in 24 equal monthly installments on the last day of each such month following the first anniversary of the Vesting Commencement Date, provided the Optionee continues to have a Service Relationship with the Company on each vesting date.

Remarks:

Exhibit 24: Power of Attorney